GPNZ Weekly Clinical Correspondence Panui 17.6.22 PHARMAC Updates •
022-06-10 Pharmac Update: Primary Care Prescribers: Pharmac review; EOI; COVID-19: Info; Adalimumab; Paracetamol; Atomoxetine; Diazoxide; Levothyroxine; Histafen; Laxsol; Methylphenidate; Nutricia; Keep up to date on supply issues and brand changes.
•
Pharmac notification: decision to fund treatments for people with breast and blood cancers. Please follow this link to the Pharmac notification regarding a decision to fund treatments for people with breast and blood cancers: o trastuzumab-emtansine (Kadcyla) for early breast cancer; and o gemtuzumab ozogamicin (Mylotarg) for people with newly diagnosed, CD33-positive acute myeloid leukaemia (AML) through an agreement with Pfizer New Zealand Ltd o azacitidine for treatment related myelodysplastic syndromes (MDS) and AML
•
Pharmac notification: decision to fund treatment earlier for relapsing remitting multiple sclerosis o Please follow this link to the Pharmac notification decision to fund treatment earlier for relapsing remitting multiple sclerosis.
•
Pharmac consultation: proposal on access criteria two COVID-19 treatments including persistent SARS-CoV-2 infection o Please follow this link to the Pharmac Consultation regarding proposed access criteria for tixagevimab with cilgavimab (Evusheld) and sotrovimab (Xevudy) for the prevention and treatment of COVID-19. o Also included in this Consultation is proposed access criteria for persistent SARS-CoV-2 infection. Pharmac welcomes feedback on this proposal. To provide feedback, please email consult@pharmac.govt.nz by 5pm on Wednesday 29 June 2022.
•
Pharmac notification: decision to widen access to antiretrovirals and nitrofura o Please follow this link to the Pharmac decision regarding proposals to make medicines more widely available for a range of uses, including human immunodeficiency virus (HIV) prevention, and urinary tract infections (UTIs).
•
Pharmac notification: decision to move access from Panel application to Special Authority process for enzyme replacement therapy for Gaucher disease o Please follow this link to the Pharmac notification decision to transition access from Panel application to Special Authority process for enzyme replacement therapy for Gaucher disease
•
2022-06-17 Pharmac Update: Primary Care Prescribers: Pharmac Review; EOI; COVID-19: Info; Adalimumab; Selegiline; Redipred; Ora-Blend- SF; Konsyl-D; Paracetamol; Atomoxetine; Diazoxide; Levothyroxine; Histafen; Laxsol; Teva; Nutricia; Keep up to date.
Nāku noa, nā Jess Morgan-French Manager, Member Services Mobile: 0211615697 Email: jess.morgan-french@gpnz.org.nz